Introduction
Interventional MRI/MRS device trials – such as studies involving MRI-guided interventions or devices used within an MRI scanner – must navigate complex regulatory frameworks to ensure patient safety and compliance. In the European Union, these trials are governed by the EU Medical Device Regulation (MDR 2017/745) and relevant national laws. These rules outline how clinical investigations of medical devices can be conducted. Special attention is required for trials involving MRI or MR spectroscopy (MRS) devices, as the MRI environment introduces unique safety considerations.
Sponsors planning such trials in the EU (and in Switzerland, which has its own aligned regulations) need to understand the applicable pathway (for example, a formal pre-market clinical investigation versus an “other” clinical investigation under MDR Article 82) and fulfill all regulatory requirements for approval.
Table of Contents
- EU Regulatory Pathways for MRI/MRS Device Trials
- Requirements under MDR Article 82
- Specific MRI/MRS Safety and Compliance Considerations
- Regulations in Switzerland
- Conclusion
EU Regulatory Pathways for MRI/MRS Device Trials
The EU MDR offers several pathways for clinical investigations, depending on the study’s aim:
| Pathway | When Used | Key Requirements |
|---|---|---|
| Article 62 – Pre-market Clinical Investigation | To gather data for CE marking of a new device or new indication. | Full MDR process: CA authorisation, Ethics Committee approval, compliance with ISO 14155:2020. |
| Article 74(1) – Post-Market Clinical Follow-up (PMCF) | For CE-marked devices used as intended, to gather additional safety/performance data. | Notification to national CA if additional procedures imposed, always requires Ethics approval. |
| Article 82 – “Other” Clinical Investigations | For trials not aimed at CE marking (investigator-led, exploratory studies). | Must meet minimum requirements (patient safety, informed consent, data protection). National CA notification or authorisation plus Ethics approval required. |
For details on these routes, see MDCG 2021-8 guidance on Article 82 investigations.
Requirements under MDR Article 82
Article 82 covers “other” clinical investigations, typically not intended for conformity assessment (CE marking). These include many academic or investigator-initiated trials. While they do not follow the same rigorous path as Article 62 studies, they must still ensure:
- Participant protection: in line with the Declaration of Helsinki and local research ethics laws.
- Device safety: the device should meet MDR Annex I general safety & performance requirements, except where being tested.
- Valid informed consent: all participants must give consent, handled by suitably qualified investigators.
- Data protection: must comply with GDPR and national privacy rules.
The MDCG 2021-8 guidance describes required documentation, like a Clinical Investigation Plan, Investigator’s Brochure, risk analysis, informed consent documents, proof of insurance, and investigator CVs. Submission to both an Ethics Committee and the national Competent Authority is generally mandatory, though exact processes vary by country.
Examples of national CA requirements
- Germany (BfArM): Ethics approval + notification via DMIDS portal for Article 82 trials.
- Austria (BASG): Full submission or notification depending on study impact on patient management.
- Belgium (FAMHP): All device trials require authorisation; coordinated with Ethics.
- Netherlands (CCMO): for Article 82, only Ethics Committee (METC) approval needed, no CA authorisation.
Specific MRI/MRS Safety and Compliance Considerations
Because MRI uses strong static magnetic fields, fast gradient fields, and high-power RF pulses, device trials in this environment require special safety evidence. Testing typically follows:
- ASTM F2503 for overall MRI safety labelling (MR Safe / MR Conditional / MR Unsafe).
- ASTM F2052 for magnetic deflection.
- ASTM F2213 for torque.
- ASTM F2182 for RF heating.
- ASTM F2119 for imaging artifacts.
Your study documentation should include results from these tests and clear MRI conditionality instructions. Protocols must describe screening, emergency procedures, and monitoring to mitigate risks like heating or device displacement.
Regulations in Switzerland
Switzerland, although not an EU member, has harmonised its laws through the Human Research Act (HRA) and ClinO-MD. Trials fall into:
- Category A: CE-marked device, used as intended (needs Ethics approval, no Swissmedic authorisation).
- Category C: non-CE device or off-label use (needs Ethics + Swissmedic authorisation).
Submit via the BASEC portal to the Ethics Committee, and to Swissmedic for Category C. Register your study on kofam.ch (SNCTP) for transparency.
Conclusion
Interventional MRI/MRS device trials demand careful planning to meet both general device investigation rules and MRI-specific safety. Sponsors must identify the correct regulatory pathway (Article 62, 74, or 82), prepare robust documentation, secure approvals from Ethics Committees and (where applicable) national authorities, and ensure all MRI hazards are managed and communicated. This diligence not only satisfies regulators but safeguards participants and upholds scientific integrity, ultimately paving the way for new MRI-guided diagnostics and therapies.